Who Qualifies for the $50 Medicare GLP-1 Bridge in 2026

The Medicare GLP-1 Bridge is a temporary federal pilot program running from July 1, 2026, through December 31, 2027, that caps out-of-pocket costs for specific FDA-approved weight-loss medications at $50 per month. To qualify, Medicare beneficiaries must be enrolled in a Part D prescription plan, meet strict Body Mass Index (BMI) and health criteria, and secure a prior authorization from a centralized processor rather than their standard insurance plan. The program covers the injectable medications Wegovy and Zepbound, alongside the newly approved once-daily pill, Foundayo.

What Is the Medicare GLP-1 Bridge?

Historically, the federal government has been strictly barred by a long-standing statute from covering medications prescribed solely for anorexia, weight loss, or weight gain under Medicare ¹²¹⁴⁵. This statutory exclusion left millions of seniors and disabled beneficiaries paying entirely out of pocket for popular and highly effective glucagon-like peptide-1 (GLP-1) receptor agonists ¹. Without insurance, these revolutionary treatments can cost anywhere from $149 to well over $1,000 per month, forcing many patients to ration doses or abandon treatment entirely ²⁶²⁸.

To bypass this statutory ban without waiting for complex Congressional legislation, the Centers for Medicare & Medicaid Services (CMS) invoked a Section 402 demonstration authority ¹²³. Section 402 allows the government to test novel approaches to healthcare delivery, premium stabilization, and drug pricing without formally amending statutory coverage rules ¹².

The resulting initiative is the Medicare GLP-1 Bridge ⁴. Beginning July 1, 2026, CMS will provide eligible Medicare Part D beneficiaries with early access to evidence-based weight-loss medications at a predictable $50 monthly copay ⁴¹¹¹². Under this framework, CMS has directly negotiated a net price of $245 per monthly supply with participating drug manufacturers ¹²³⁵. The patient pays $50 at the pharmacy counter, and the remaining costs are managed by a central processor ⁵¹⁴⁶. This structure allows CMS to collect vital utilization data and provide immediate financial relief to patients without exposing standard Medicare Part D plan sponsors to the financial risk of these expensive therapies ⁵⁶¹⁶.

The Policy Landscape: Why Is Coverage Changing Now?

The path to covering GLP-1s in Medicare has been politically fraught and economically complex. In late 2025, the proposed contract year 2026 Medicare Advantage and Part D rule included sweeping provisions that would have formally expanded coverage to weight loss medications for all Medicare and Medicaid beneficiaries dealing with obesity ¹²⁴.

However, the Congressional Budget Office (CBO) published a report in October 2024 analyzing the massive economic impact of such a change, concluding that covering GLP-1 drugs for obesity would cost the Medicare program an estimated $35 billion between 2026 and 2034 ⁴. Fearing premium spikes and budget destabilization, the final CY 2026 MA and Part D rule ultimately removed these broad coverage provisions ¹².

To soften the blow of this reversal, the Trump administration announced an alternative strategy in November 2025. They unveiled agreements with the manufacturers of brand-name GLP-1 products to reduce consumer prices through a new direct-to-consumer platform known as TrumpRx, while simultaneously initiating the Medicare GLP-1 Bridge and the multi-year BALANCE Model demonstration projects ¹²⁴. This policy pivot represents a significant departure from the government's historical stance, aiming to balance the undeniable clinical benefits of obesity treatment with the severe fiscal constraints of the Medicare program ¹²⁴.

Which Weight Loss Medications Are Covered?

The GLP-1 Bridge program covers three specific FDA-approved GLP-1 medications when prescribed for chronic weight management. The program is exclusive to these branded therapies; it currently excludes older weight-loss drugs like phentermine-topiramate (Qsymia) or naltrexone-bupropion (Contrave) ³¹¹¹⁷.

1. Foundayo (orforglipron)

Approved by the FDA on April 1, 2026, Foundayo represents a major technological leap in obesity treatment ^7891022. Manufactured by Eli Lilly, Foundayo is an oral glucagon-like peptide-1 (GLP-1) receptor agonist ⁷¹⁰. However, unlike earlier pill-based treatments, its active ingredient, orforglipron, is a small-molecule, non-peptide compound ^7891023.

Peptide-based drugs are highly unstable in the acidic environment of the human stomach and require strict fasting protocols to be absorbed properly ⁸⁸⁹. Foundayo's non-peptide structure solves this problem. It can be taken once a day at any time, with or without food, and without strict water limitations, offering unprecedented flexibility for patients ⁸⁷⁸⁹¹¹.

The FDA approval of Foundayo was heavily supported by the ATTAIN clinical trial program ¹⁰²³. In the ATTAIN-1 trial, which evaluated adults with obesity but without diabetes, participants taking the highest dose of Foundayo (17.2 mg) and completing the trial lost an average of 12.4% of their baseline body weight (an average of 27.3 pounds) over 72 weeks, compared to just 0.9% in the placebo group ⁸⁹¹⁰¹². When looking at all participants regardless of whether they completed the full trial, the average weight loss was 11.1% (25 pounds) ⁷¹⁰.

Like other GLP-1s, Foundayo works by binding to receptors in the brain to reduce hunger, increase feelings of fullness, and slow gastric emptying ⁷⁸¹⁰. It does carry standard class warnings, including a boxed warning for the potential risk of thyroid C-cell tumors, alongside monitoring requirements for gastrointestinal distress, acute kidney injury, and pancreatitis ⁷¹⁰²³. All dosage formulations of Foundayo (from 0.8 mg up to 17.2 mg) are fully covered under the Bridge program ^3782226.

2. Wegovy (semaglutide)

Manufactured by Novo Nordisk, Wegovy is covered under the Bridge in both its traditional once-weekly injectable form and its daily oral tablet form ²³¹¹⁵. Its active ingredient, semaglutide, has a long track record of safety and efficacy, and is identical to the ingredient used in the diabetes drug Ozempic ^81782713.

In pivotal clinical trials (such as the STEP 1 trial), injectable Wegovy demonstrated an average body weight reduction of approximately 14.9% to 15% over 64 to 71 weeks ¹⁷⁹²⁷. The newer daily oral version of Wegovy, which was approved in late 2025, showed similar or slightly superior efficacy, with the OASIS clinical trial demonstrating up to 16.6% average weight loss ¹⁷⁹²⁷. In addition to weight reduction, Wegovy carries secondary FDA approvals for reducing the risk of major adverse cardiac events and treating non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) ¹⁷.

Despite the convenience of a pill, the oral formulation of Wegovy is a modified protein (peptide) and remains notoriously difficult for the body to absorb ⁸⁸⁹. It requires strict morning fasting: it must be taken on an empty stomach with no more than four ounces of water, and the patient must wait at least 30 minutes before eating, drinking, or taking any other medications ^8892713.

3. Zepbound (tirzepatide)

Eli Lilly's injectable Zepbound uses the active ingredient tirzepatide (the same compound used in the diabetes medication Mounjaro) ^1781227. Zepbound is unique among the Bridge-covered drugs because it is a dual agonist; it mimics both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) ¹⁷⁹¹². By targeting two distinct appetite-regulating hormone pathways simultaneously, Zepbound currently boasts the highest average weight loss among approved anti-obesity medications ^1217912.

In the landmark SURMOUNT-1 clinical trial, adults with obesity taking tirzepatide achieved an average body weight reduction of between 15% and 22.5% over 72 weeks, depending on the dosage ¹⁷¹².

Crucial restriction: Under the Medicare GLP-1 Bridge, only the KwikPen formulation of Zepbound is eligible for the $50 copay ³²⁶¹⁴. The single-dose vial and standard single-dose pen formulations of Zepbound are strictly excluded from the demonstration program ³²⁶¹⁴.

Medication Comparison Summary

The table below summarizes the key features, administration routes, and clinical trial efficacy benchmarks for the medications included in the Medicare GLP-1 Bridge.

Note: Efficacy percentages are derived from varied clinical trials (ATTAIN, STEP/OASIS, and SURMOUNT programs) and are heavily dependent on dosage, patient adherence, and lifestyle modifications ^{831778910221227}.

Who Qualifies for the $50 Copay?

Not every Medicare beneficiary can access the GLP-1 Bridge. The program operates with highly specific enrollment boundaries and clinical criteria that are notably more restrictive than general FDA prescribing labels ³¹²³⁰.

1. Medicare Plan Requirements

To qualify, a patient must be actively enrolled in a qualifying Medicare prescription drug plan for the 2026 calendar year ³¹¹⁵³⁰. Eligible plans include: * Standalone Medicare Part D Prescription Drug Plans (PDPs) ^3115141430. * Medicare Advantage coordinated care plans that include prescription drug coverage (MA-PDs), such as HMOs and PPOs ^3115141430. * Special Needs Plans (SNPs) and the Limited Income Newly Eligible Transition (LI NET) program ^31151614. * Employer/union group waiver plans (EGWPs) ³¹¹¹⁴.

Certain specialized plan types are explicitly excluded. Beneficiaries enrolled in private fee-for-service plans, section 1876 cost contract plans, PACE organizations, or religious fraternal benefit plans cannot participate unless they simultaneously carry a standalone PDP ³. Furthermore, TRICARE For Life beneficiaries are only eligible if they are cross-enrolled in an eligible Medicare Part D plan and successfully meet all clinical prior authorization criteria ³.

2. Strict Clinical and BMI Criteria

You must be at least 18 years old, and your healthcare provider must attest that the medication is being prescribed specifically to reduce excess body weight and maintain weight reduction in combination with ongoing lifestyle modifications, such as structured nutrition and physical activity ^3121414.

Furthermore, a physician must verify that the patient met one of three specific Body Mass Index (BMI) tiers.

Source: CMS Medicare GLP-1 Bridge Provider Guidelines ^13125141415.

The "Lookback" Rule: A critical and highly beneficial feature of the program is that the BMI criteria apply to the moment the patient first initiated GLP-1 therapy, rather than their current weight ³¹⁴¹⁴. For example, if a patient began taking Wegovy out-of-pocket in September 2024 with a starting BMI of 37, but their current BMI has dropped to 34 by the time of their July 2026 prior authorization request, they still fully qualify ³¹⁴. The prescribing provider simply attests to the original BMI at the time therapy was initiated, ensuring that patients are not financially punished for successfully losing weight prior to the Bridge's launch ³¹⁴¹⁴.

3. Excluded Diagnoses

The Medicare GLP-1 Bridge is exclusively designed to cover medications prescribed for weight management ³¹⁴¹⁴. If a beneficiary requires a GLP-1 medication to treat Type 2 diabetes, obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), they cannot use the GLP-1 Bridge ^1431214.

This is because standard Medicare Part D plans are already legally permitted - and routinely expected - to cover GLP-1s for these specific, FDA-approved non-weight-loss indications ¹⁴³¹⁴. Patients with these conditions must obtain their prescriptions through their normal Part D benefit flow, paying whatever formulary copay or coinsurance their specific insurance plan dictates. Even if that standard Part D copay is higher than $50, the patient is locked out of the Bridge program ¹³¹⁴.

Financial Mechanics: How the $50 Copay Works (and the TrOOP Catch)

When a prior authorization is approved, the beneficiary's out-of-pocket cost is strictly capped at $50 for a 30-day supply of the medication ^2634111416. Patients cannot stack additional manufacturer coupons, savings cards, or secondary discounts to lower this $50 copay any further ¹⁴.

However, the financial mechanics of this program come with a significant structural catch that beneficiaries must fully understand: The Medicare GLP-1 Bridge operates entirely outside of the standard Medicare Part D benefit structure ^{1562311562616}.

Because the program is an experimental Section 402 demonstration, the financial claims bypass your private insurance company entirely ⁵⁶⁵¹⁴⁶. Instead, CMS uses a single, centralized processor (contracted through Humana) to adjudicate the claims and pay the dispensing pharmacies directly ^611514614. At the pharmacy counter, the patient pays the $50 copay, and the central processor reimburses the pharmacy for the remainder of the $245 negotiated wholesale acquisition cost (plus a standard dispensing fee) ¹²³⁵¹⁴.

Because this money never flows through your Part D plan's accounting systems, patients face three distinct financial consequences:

1. No Deductible Assistance: The $50 you spend each month on Wegovy, Zepbound, or Foundayo will not count toward satisfying your annual Part D deductible ^1311151633.
2. No TrOOP Accumulation: Neither the $50 copay nor the $245 net cost of the drug counts toward your True Out-Of-Pocket (TrOOP) spending or your gross covered prescription drug costs (GCPDC) ^1311516. In 2026, standard Part D plans feature a $2,100 annual out-of-pocket spending cap; money spent in the Bridge program will not help you reach that protective limit ^1111533.
3. No "Extra Help" Subsidies: If you are a low-income senior who qualifies for the Part D Low-Income Subsidy (LIS) program - commonly known as Extra Help - you cannot apply those federal subsidies to Bridge prescriptions ³¹¹¹⁶. You will still be required to pay the full, unsubsidized $50 copay ³¹¹¹⁶.

Despite these limitations, the flat $50 rate remains consistent regardless of which phase of the Part D benefit (such as the coverage gap or catastrophic phase) the beneficiary is currently traversing for their other medications ³.

The Prior Authorization Process for 2026

Beneficiaries cannot enroll themselves directly into the Bridge program; the application process relies entirely on active coordination by medical providers ¹¹³⁰.

1. Wait for the Launch Date: The program does not formally begin until July 1, 2026. Providers are instructed not to submit any paperwork early, as prior authorization requests will not be accepted, queued, or processed before that date ³¹⁴.

2. Provider Submission: To initiate coverage, a medical provider must submit both a valid prescription and a specific prior authorization request directly to the CMS central processor ³⁵¹⁴. Providers can submit this documentation electronically - which CMS strongly encourages to prevent backlogs - or via a standardized fax form that will be published in June 2026 ³¹⁴.

3. Minimal Provider Friction: CMS has intentionally removed barriers for physicians. A doctor does not need to be formally enrolled as a Medicare provider to write a Bridge prescription or submit a prior authorization request ¹²¹⁴. The only restriction is that the prescribing provider must not be listed on the federal Medicare Preclusion List ¹⁴.

4. Plan Independence: Because the central processor handles the claims, your specific Part D insurance sponsor does not need to "opt in" or assume any risk for you to gain access ⁶²¹¹⁵⁶. If a standard Part D plan inadvertently receives a prior authorization request for a weight-loss medication covered under the Bridge, CMS guidelines mandate that the plan immediately direct the provider to reroute the request to the central processor ⁵.

For patients who are currently rationing doses due to high cash-pay costs, healthcare advocates and clinic navigators strongly suggest consulting with doctors well before the July 1 launch ⁶¹¹³⁰. Gathering baseline BMI records, confirming cardiovascular comorbidities, and preparing the necessary attestation paperwork early will be critical for avoiding administrative bottlenecks when the central processor portal opens ⁶¹¹³⁰.

The BALANCE Model: What Happens in 2028?

The program is officially designated as a "Bridge" because it serves as a temporary, 18-month stopgap ^16211514634.

It is designed to provide immediate access and collect real-world utilization data while the government builds a much larger, permanent infrastructure known as the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model ^{15611514616263417}.

The BALANCE Model is a multi-year demonstration project that fundamentally shifts how Medicare handles weight-loss drugs ¹⁵¹⁷. Under BALANCE, CMS abandons the central processor approach and instead negotiates directly with drug manufacturers on behalf of participating Part D plan sponsors and state Medicaid agencies to permanently integrate affordable GLP-1 coverage into standard insurance benefits ⁵²⁶¹⁷.

Originally, BALANCE was scheduled to launch across both Medicare and Medicaid on January 1, 2027 ^{162115146163417}. The Medicaid portion is proceeding as planned, with states allowed to opt into the pricing model between May 2026 and January 2027 ^2526162617.

However, the Medicare Part D rollout encountered a massive roadblock. To launch BALANCE in Medicare, CMS required enough Part D insurance plans to voluntarily sign up to cover at least 80% of eligible beneficiaries ⁵. In April 2026, CMS announced that too few major insurers - including holdouts like UnitedHealth Group and CVS Health - were willing to participate and absorb the financial risk ⁵²¹¹. Consequently, CMS was forced to delay the Medicare implementation of BALANCE until at least 2028 ⁵.

To prevent seniors from losing access in the interim, CMS officially extended the temporary GLP-1 Bridge through December 31, 2027 ^{156211514162634173637}.

This delay highlights a critical future risk for patients: when the BALANCE Model eventually launches in Medicare, participation will be voluntary for Part D insurers ¹⁵²⁶. This means that beneficiaries utilizing the Bridge program in 2026 and 2027 will likely need to carefully evaluate and potentially switch their Part D plans during the 2027 open enrollment period, ensuring they select a plan that has formally opted into the BALANCE framework for 2028 ¹¹¹. Failing to switch to a participating plan could result in a sudden loss of coverage and a return to exorbitant out-of-pocket prices for life-saving obesity care ¹¹¹.

Bottom line

Starting July 1, 2026, the Medicare GLP-1 Bridge will provide eligible Part D enrollees with unprecedented access to Wegovy, Zepbound (KwikPen), and the newly approved oral pill Foundayo for a predictable $50 monthly copay. Because the program operates entirely outside normal Medicare Part D benefits via a central processor, your $50 payments will not count toward your annual deductible or your $2,100 out-of-pocket maximum. While the Bridge secures affordable access through December 2027, the voluntary nature of the subsequent BALANCE Model means patients must remain vigilant during future open enrollment periods to ensure their coverage continues uninterrupted in 2028.